Hem

Press release from Companies

Publicerat: 2022-07-15 10:12:00

RhoVac AB: RhoVac's CEO, Anders Månsson, has tendered his resignation

RhoVac AB ("RhoVac"), announces today, July 15 2022, that the company's CEO, Anders Månsson, has announced his wish to leave his position with the company no later than after the 3-month stipulated notice period.

Pending a final decision regarding the company's future, RhoVac's CEO, Anders Månsson, has decided to give notice of termination of his employment with the company, and he will leave RhoVac no later than September 30.

Gunnar Gårdemyr, Chairman of the Board; "I wish Anders Månsson all the best in his new endeavours and sincerely thank him for his period as CEO of RhoVac. Anders did an excellent job, not least regarding the company's communication, both in success and adversity. We had a well-prepared exit process that could have been executed if only the crucial study, BRaVac, had reached its primary objective."

Furthermore, the Board has not ruled out a possible merger with another company, in which case such a company will need to be headed by another CEO.

An Extraordinary General Meeting will be convened shortly to decide on the alternatives available to the company given the situation that has arisen after BRaVac.


This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-07-2022 10:12 CET.

For more information, please contact:
Anders Månsson – CEO, RhoVac AB
Phone: +46 73 751 7278
E-mail:
info@rhovac.com

On RhoVac AB
RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has passed the early stages of development.
In 2019, patient recruitment began for a larger clinical phase IIb study that included more than 180 patients with prostate cancer. The Top Line results were presented in May 2022. Further data are currently being evaluated. RhoVac is listed on the Spotlight Stockmarket. The share is traded under the ticker RHOVAC. More information is available at www.rhovac.com.

Läs mer hos Cision
Läs mer om RhoVac AB

Prenumeration